Neurim wins the battle but not (yet) the war for innovators
This article was originally published in SRA
Mike Snodin and Michael Pears argue that while the EU decision on supplementary protection certificates might be good news for companies that find new uses for "old" active ingredients, it raises more questions than it answers and leaves lingering uncertainty for many other companies.
You may also be interested in...
The US agency has pushed to next month a public meeting on the latest incarnation of the Medical Device User Fee Amendments. The meeting will be held remotely.
Experts from the University of Chicago are advocating for helmet ventilation for COVID-19 patients. Medtech Insight spoke to acute nurse practitioner Aurika Savickaite who is helping lead an initiative to educate and raise awareness of the technology.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.